SynthesisOncotarget2017
Prognostic value of progesterone receptor expression in ovarian cancer: a meta-analysis.
Synthesis in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07356466 (Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Center Randomized Controlled Trial
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Hormone replacement therapy after surgery for epithelial ovarian cancer.The Cochrane database of systematic reviews · 2020Pooled it
- Signaling Pathway Dissection After Progesterone Receptor Enhancement in an Immortalized Pre-Cancer Fallopian Tube Epithelial Cell Line.International journal of molecular sciences · 2026Article
- Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis.Gynecologic oncology · 2025Article
- Ecological and evolutionary dynamics to design and improve ovarian cancer treatment.Clinical and translational medicine · 2024Review
- How Progesterone Receptor Expression Impacts Platinum Sensitivity in Ovarian Clear Cell Carcinoma: Insights from Clinical and Experimental Perspectives.International journal of molecular sciences · 2024Article
- Hormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options.Biomedicines · 2023Review
- Chemerin and Chemokine-like Receptor 1 Expression in Ovarian Cancer Associates with Proteins Involved in Estrogen Signaling.Diagnostics (Basel, Switzerland) · 2023Article
- Expression of Progesterone Receptor A as an Independent Negative Prognosticator for Cervical Cancer.International journal of molecular sciences · 2023Article
- Molecular Management of High-Grade Serous Ovarian Carcinoma.International journal of molecular sciences · 2022Review
- Role of NRF2 in Ovarian Cancer.Antioxidants (Basel, Switzerland) · 2022Review
- AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin.Scientific reports · 2022Article
- The Flavonoid Baicalein Negatively Regulates Progesterone Target Genes in the UterusJournal of natural products · 2022Article
- Article
- Progesterone receptor gene serves as a prognostic biomarker associated with immune infiltration in gastric cancer: a bioinformatics analysis.Translational cancer research · 2021Article
- Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer.Bioscience reports · 2021Article
- Fallopian tube initiation of high grade serous ovarian cancer and ovarian metastasis: Mechanisms and therapeutic implications.Cancer letters · 2020Review
- Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology.Cancer management and research · 2019Article
- Cadmium induces progesterone receptor gene expression via activation of estrogen receptor in human ovarian cancer cells.Research in pharmaceutical sciences · 2018Article
- Estrogen receptor β is associated with expression of cancer associated genes and survival in ovarian cancer.BMC cancer · 2018Article
- Irilone from Red Clover ( Trifolium pratense) Potentiates Progesterone Signaling.Journal of natural products · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWhile a prognosis value of progesterone receptor (PR) in ovarian cancer has been reported in some publications, controversial data were presented by different reports. In order to address the disagreement of progesterone receptor in ovarian cancer survival, we conducted this meta-analysis.
methodsRelevant articles on progesterone receptor and ovarian cancer prognosis were identified via a thorough search of PubMed, Embase and Cochrane Central. Hazard ratios (HR) and 95% confidence interval (CI) were extracted from studies on overall survival (OS) and disease-free survival (DFS)/progress-free survival (PFS)/recurrence-free survival (RFS).
resultA total of 28 eligible studies containing 5685 patients were collected for analysis. It was found that progesterone receptor positivity was significantly associated with favorable overall survival (OS) (HR = 0.86, 95% CI = 0.78 to 0.95, P = 0.002) and disease-free survival (DFS)/progress-free survival (PFS)/recurrence-free survival (RFS) (HR = 0.75, 95% CI = 0.61 to 0.93, P = 0.008) of ovarian cancer patients. Subgroup analysis showed that progesterone receptor expression was associated with a favorable prognosis of unclassified ovarian cancer, European origin, and immunohistochemical detection method.
conclusionProgesterone receptor expression can be used as a favorable prognostic predictor in ovarian cancer managements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.